O

Orchard Therapeutics

Autologous gene therapies for rare diseases.

HR Systems & Data Analyst

Full-TimePosted on 10/21/2026
No salary listed
Mid
London, UK
Hybrid
People & HRHR Operations & Coordination

About the job

Requirements
  • High level of IT literacy, including data and reporting tools, and fluency in Microsoft Excel.
  • Proven experience administering and supporting an HR information system, ideally as an HRIS administrator or super user.
  • Experience maintaining confidential data and ensuring data quality and integrity.
  • Understanding of HR processes and employee data.
  • Experience working with data, identifying trends or insights, and producing high-quality analysis and reports.
  • Experience supporting benefits administration and/or wider HR operational processes.
  • Experience working collaboratively on HR projects and process improvements.
  • Ability to handle confidential and sensitive employee information appropriately.
  • Strong analytical and numerical skills.
  • High level of accuracy and attention to detail.
  • Strong problem-solving skills, including investigating issues and identifying practical solutions.
  • Ability to manage competing priorities and work to deadlines.
  • Ability to work independently and take ownership of responsibilities.
  • Ability to communicate technical subject matter clearly to non-technical colleagues and work effectively with a range of stakeholders.
  • Proactive approach to identifying opportunities for continuous improvement.
  • Flexible and collaborative approach, with willingness to contribute across the wider HR function and participate in HR projects.
Responsibilities
  • Administer the HR information systems day to day and act as the super user, advising and supporting HR colleagues and system users.
  • Identify opportunities to improve HR processes through better use of systems, automation, and technology.
  • Seek use cases for artificial intelligence within HR processes.
  • Maintain accurate and up-to-date employee data in HR systems, ensuring data integrity and quality throughout the employee lifecycle, including onboarding and offboarding.
  • Manage system configuration, workflows, user access, and scheduled system changes.
  • Investigate and resolve system issues, working with internal teams and external providers as needed.
  • Support system testing, upgrades, releases, and implementation of new functionality.
  • Support HR systems integration and development, including collaboration on wider business systems initiatives.
  • Maintain system documentation, processes, and guidance.
  • Support and, where appropriate, lead HR systems, reporting, and process-improvement projects.
  • Develop and maintain reports, dashboards, and other HR data outputs; produce accurate and timely HR reports and management information.
  • Analyze HR data to identify trends, themes, and insights, and support informed decision-making through data-driven storytelling.
  • Support preparation of HR presentations and information for senior stakeholders.
  • Respond to ad hoc reporting and data-analysis requirements.
  • Maintain high standards of data governance, accuracy, consistency, and integrity.
  • Administer EMEA employee benefits day to day and liaise with benefit providers as required.
  • Maintain accurate benefits information within HR systems.
  • Support employee and HR queries relating to benefits and HR processes.
  • Support relevant employee lifecycle and wider HR operational processes.
  • Work closely with payroll and other internal teams where HR systems, data, and benefits processes overlap.
Desired Qualifications
  • Experience supporting HRIS configuration, implementation, upgrades, integrations, or significant system change.
  • Experience using Sage People.
  • Experience working with HR technology providers or survey platforms.
  • Experience developing dashboards or more advanced HR analytics.
  • Demonstrable artificial intelligence literacy and use cases.
  • A relevant HR, data, business, systems, or analytical qualification or professional development may be advantageous, but is not required.

About the company

Orchard Therapeutics develops autologous ex vivo gene therapies to treat rare, life-threatening genetic diseases. Its approach collects a patient’s hematopoietic stem cells, edits a functional gene outside the body, and reinserts the corrected cells to rebuild the blood and immune system. The company differentiates itself by delivering single-dose, patient-specific cures that aim to address the disease at its source, with Libmeldy/Lenmeldy as its approved product and a clinical-stage pipeline for other conditions. Orchard’s goal is to provide safe, one-time therapies for children with severe genetic disorders and to expand a portfolio of approved and investigational gene therapies through its Kyowa Kirin ownership.

Company Size

201-500

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

2015

Get referred to Orchard Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Kyowa Kirin’s February 3, 2026 £11 million UK investment funds Orchard’s development base.
  • OTL-203 finished enrollment nearly one year early on July 7, 2025, accelerating value inflection.
  • Lenmeldy reimbursement keeps expanding, including Beneluxa access and U.K. NHS availability.

What critics are saying

  • Revenue still hinges on Lenmeldy and Libmeldy; one launch failure cripples Kyowa Kirin’s rare-disease bet.
  • OTL-201 remains unapproved; a proof-of-concept stumble would freeze Orchard’s next-product story.
  • Bluebird, academic transplant centers, and newborn screening programs keep pressuring MLD adoption through 2027.

What makes Orchard Therapeutics unique

  • Libmeldy and Lenmeldy are the first approved ex vivo HSC gene therapies for early-onset MLD.
  • Orchard’s 2026 OTL-201 ILAP designation shows UK regulators still back its HSC platform.
  • OTL-203’s July 7, 2025 registrational trial beat standard allogeneic HSCT head-to-head.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

1%

1 year growth

1%

2 year growth

3%
BioPharm International
Apr 8th, 2026
Orchard Therapeutics announces new gene therapy manufacturing facility.

Orchard Therapeutics announces new gene therapy manufacturing facility. A new facility in California will expand Orchard Therapeutic's capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells. Orchard Therapeutics announced in a Dec. 13, 2018 press release that it signed a long-term lease agreement to build out a gene therapy manufacturing facility in Fremont, CA. The new 150,000-ft[2] facility adds to the Foster City and Menlo Park, CA sites, which oversee the ongoing development and validation of the manufacture of Orchard's ex vivo gene therapy product candidates. Once operational, the new site will provide cGMP manufacturing capacity for both lentiviral vector and cryopreserved cell therapy products, enhancing Orchard's ability to manufacture and deliver gene-corrected hematopoetic stem cells for a range of diseases on a global basis. In addition to this expanded capacity, the company also plans to continue its collaborations with its contract manufacturing partners. "The expansion of our California operations to now include a manufacturing facility is a critical step in advancing Orchard's capabilities to supply products for our ex vivo gene therapy programs," said Stewart Craig, chief manufacturing officer of Orchard Therapeutics, in the press release. "We believe that this new facility, as an early investment in our own manufacturing, will not only drive efficiencies and scalability in terms of lentiviral vector and drug product development, it will also complement the capabilities of our existing vector and drug product manufacturing partners to support the potential launch of our gene therapy clinical product candidates." The build-out of Orchard's new manufacturing facility is expected to begin in 2019, and the company expects to hire more than 100 full-time employees over the next few years to support in-house manufacturing efforts. Stay at the forefront of biopharmaceutical innovation - subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Marcom Globe Italy
Oct 7th, 2024
Orchard Therapeutics and Er-Kim Announce Partnership to Broaden Access to Libmeldy to Eligible Patients in Turkey and Certain Eurasian Countries

Er-Kim will collaborate with Orchard Therapeutics to refer eligible children with early-onset MLD identified in these countries to an established European-based qualified treatment center.

UnLimited Media
Mar 29th, 2024
French indie label body UPFI calls on French government to intervene in potential Warner Music Group takeover of Believe

Believe "embodies a model of success and resistance to the worrying phenomenon of consolidation at work in the sector that has seen the successive acquisition of many significant distributors", it adds, highlighting Sony Music's acquisition of The Orchard and AWAL.

BioSpace
Mar 19th, 2024
Orchard Wins Fda Approval For First Gene Therapy For Rare Pediatric Disease

Pictured: FDA signage at its headquarters in Maryland/iStock, hapabapaThe FDA on Monday approved Orchard Therapeutics’ autologous gene therapy atidarsagene autotemcel, which will now be marketed as Lenmeldy, for the treatment of metachromatic leukodystrophy in pediatric patients.Lenmeldy is the first authorized gene therapy for children with pre-symptomatic late infantile or early juvenile metachromatic leukodystrophy (MLD), according to the FDA’s press release on the approval. Lenmeldy is also the first approved therapy for early juvenile or early symptomatic forms of the disease.Orchard CEO Bobby Gaspar in a statement said that Lenmeldy’s approval “opens up tremendous new possibilities” for children suffering from these early-onset forms of MLD, “who previously had no treatment options beyond supportive and end-of-life care.”The company on Monday did not provide specific launch details for Lenmeldy but promises to do so within the week.MLD is a rare and heritable metabolic disease that affects one in every 100,000 live births. It is characterized by a pathological build-up of sulfatides in the brain, liver, kidneys, spleen and other body parts, which over time can cause organ damage and neurological issues. Those with MLD often suffer from motor, behavioral and cognitive problems, as well as seizures. Patients also slowly lose the ability to move, talk, swallow and eat.Children with MLD often degenerate to a vegetative state and require round-the-clock care. Most patients die within five years of disease onset.MLD is caused by a mutation in the arylsulfatase-A (ARSA) gene, which under healthy circumstances produces an enzyme that breaks down sulfatides

Ochre Digi Media Pvt Ltd.
Jan 26th, 2024
Orchard Therapeutics Enters Agreement with Beneluxa Consortium to Facilitate Reimbursed Access to Libmeldy

Orchard Therapeutics enters agreement with Beneluxa consortium to facilitate reimbursed access to Libmeldy.